The over-arching goal of the Healthy Aging and Senile Dementia (HASD) study is to determine the factors that signal the imminent development of symptomatic Alzheimer disease (AD) in cognitively normal older adults. In pursuing this goal, HASD also will examine whether these predictive factors differ between African Americans and non-Hispanic whites, are influenced by sleep, or might be offset by genetic variants that protect against developing symptomatic AD. Finally, HASD will evaluate a novel method of assessing cognitive performance in naturalistic settings via a smartphone application. To accomplish these goals, HASD will assess and follow a richly phenotyped cohort that includes both cognitively normal older adults (~75%) and those with early-stage symptomatic AD (~25%). The longitudinal assessment protocol includes standard and novel clinical and cognitive measures, a six-day in-home sleep study, magnetic structural imaging studies of the brain, positron emission tomography studies of the brain to reveal the cerebral hallmarks of AD, amyloid-beta plaques and tau deposition, and examination of blood for genetic studies and of cerebrospinal fluid for levels of amyloid-beta and tau. Five Cores (Administration, Clinical, Biostatistics, Neuropathology [includes the Biofluids Laboratory], and Imaging) will support four Projects that carry out the scientific aims of HASD: Project 1: ?Characterization of Molecular Biomarker Profiles of AD throughout its Pathobiological Continuum? Project 2: ?Sleep and Orexin: Potential Markers of Progression from Preclinical to Mildly Symptomatic Alzheimer Disease? Project 3: ?Dissecting the Genetic Architecture of Resilience? Project 4: ?Smartphone-Based `Burst' Cognitive Assessments?

Public Health Relevance

The over-arching goal of the Healthy Aging and Senile Dementia (HASD) study is to determine those factors that signal the imminent development of Alzheimer disease (AD) in cognitively normal older adults. In pursuing this goal, HASD also will examine whether these predictive factors differ between African Americans and non- Hispanic whites, are influenced by sleep, or might be offset by genetic variants that protect against developing symptomatic AD. Finally, HASD will evaluate a novel method of assessing cognitive performance in naturalistic settings via a smartphone application.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
5P01AG003991-37
Application #
9914167
Study Section
Special Emphasis Panel (ZAG1)
Program Officer
Hsiao, John
Project Start
1997-01-01
Project End
2024-04-30
Budget Start
2020-05-01
Budget End
2021-04-30
Support Year
37
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Washington University
Department
Neurology
Type
Schools of Medicine
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Aschenbrenner, Andrew J; Gordon, Brian A; Benzinger, Tammie L S et al. (2018) Influence of tau PET, amyloid PET, and hippocampal volume on cognition in Alzheimer disease. Neurology 91:e859-e866
Day, Gregory S; Musiek, Erik S; Morris, John C (2018) Rapidly Progressive Dementia in the Outpatient Clinic: More Than Prions. Alzheimer Dis Assoc Disord 32:291-297
Karch, Celeste M; Hernández, Damián; Wang, Jen-Chyong et al. (2018) Human fibroblast and stem cell resource from the Dominantly Inherited Alzheimer Network. Alzheimers Res Ther 10:69
Villeneuve, Sylvia; Vogel, Jacob W; Gonneaud, Julie et al. (2018) Proximity to Parental Symptom Onset and Amyloid-? Burden in Sporadic Alzheimer Disease. JAMA Neurol 75:608-619
Day, Gregory S; Gordon, Brian A; Perrin, Richard J et al. (2018) In vivo [18F]-AV-1451 tau-PET imaging in sporadic Creutzfeldt-Jakob disease. Neurology 90:e896-e906
Sato, Chihiro; Barthélemy, Nicolas R; Mawuenyega, Kwasi G et al. (2018) Tau Kinetics in Neurons and the Human Central Nervous System. Neuron 97:1284-1298.e7
Lewczuk, Piotr; Riederer, Peter; O'Bryant, Sid E et al. (2018) Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. World J Biol Psychiatry 19:244-328
Vardarajan, Badri N; Barral, Sandra; Jaworski, James et al. (2018) Whole genome sequencing of Caribbean Hispanic families with late-onset Alzheimer's disease. Ann Clin Transl Neurol 5:406-417
Joseph-Mathurin, Nelly; Su, Yi; Blazey, Tyler M et al. (2018) Utility of perfusion PET measures to assess neuronal injury in Alzheimer's disease. Alzheimers Dement (Amst) 10:669-677
Pottier, Cyril; Zhou, Xiaolai; Perkerson 3rd, Ralph B et al. (2018) Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. Lancet Neurol 17:548-558

Showing the most recent 10 out of 911 publications